Delhi HC asks Natco Pharma to pause Risdiplam launch amid patent dispute

The Delhi High Court has ordered Natco Pharma to maintain status quo on the launch of Risdiplam until April 2. Roche, which holds the patent for the drug, sought an injunction to prevent Natco from manufacturing it in India. The court highlighted the public interest in making the drug affordable.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kI9mxiE
via IFTTT